
**PHARMAXIS STRENGTHENS CLINICAL DEVELOPMENT
ONCOLOGY CAPABILITY WITH THE APPOINTMENT OF
DR JANA BASKAR AS CHIEF MEDICAL OFFICER**

Pharmaxis Limited (ASX:PSX), a clinical stage drug development company developing novel therapies to treat inflammatory and fibrotic diseases, is pleased to announce the appointment of Dr Jana Baskar to the role of Chief Medical Officer.

Dr Baskar is a highly experienced executive who has worked in both pharmaceutical and contract research companies.

“We are delighted to welcome Dr Baskar to Pharmaxis, where his deep experience leading clinical programs will be an asset to the continued advancement of our pipeline,” commented Gary Phillips, Chief Executive Officer of Pharmaxis. “Dr Baskar brings significant oversight, clinical development and strategic expertise, having previously guided numerous programs through all phases of development. His extensive background and experience will be particularly valuable as the Company progresses its lead asset, PXS-5505, towards clinical proof of concept in myelofibrosis and other oncology indications.”

Dr Jana Baskar has over two decades of experience including overseeing more than 70 phase I-III trials of oncology treatments in his 6 years as Medical Director at Novartis Oncology in Australia. In his most recent role, he served as Medical Director for IQVIA in Australia and New Zealand where he also co-chaired the IQVIA ANZ Oncology Advisory Board providing strategic advice to Biopharma companies. Dr Baskar received his Bachelor of Medicine degree (MBBS) from the University of Western Australia. He holds a Master of Medical Science in Drug Development from the University of New South Wales, Sydney (MMedSc) and a Masters of Business Administration (MBA) from the Australian Graduate School of Management.

Pharmaxis founding scientist and Medical Director, Dr Brett Charlton, is retiring after more than 20 years’ service with the company during which time he has overseen development programs that lead to two products achieving global regulatory approval and the transition of several pipeline products into clinical development including Pharmaxis’ two lead assets in myelofibrosis (PXS-5505) and scarring (PXS-6302).

Gary Phillips said, "I'd like to recognise and sincerely thank Dr Charlton for his extensive contribution to the Pharmaxis business and to advances in patient care. His experience and knowledge of transitioning drugs into early phase development has been extremely valuable and we will continue to seek his advice in a part time consultancy capacity until the end of 2022."

Ends

SOURCE: Pharmaxis Ltd, Sydney, Australia

AUTHORISED FOR RELEASE TO ASX BY:

Pharmaxis Ltd Disclosure Committee. Contact: David McGarvey, Chief Financial Officer and Company Secretary: T +61 2 9454 7203, E david.mcgarvey@pharmaxis.com.au

CONTACTS:

Media: Felicity Moffatt: T +61 418 677 701, E felicity.moffatt@pharmaxis.com.au

Investor relations: Rudi Michelson (Monsoon Communications) T +61 411 402 737, E rudim@monsoon.com.au

Join the Pharmaxis mailing list [here](#)

Follow us:



About Pharmaxis

Pharmaxis Ltd is an Australian clinical stage drug development company developing drugs for inflammatory and fibrotic diseases, with a focus on myelofibrosis. The company has a highly productive drug discovery engine built on its expertise in the chemistry of amine oxidase inhibitors, with drug candidates in clinical trials. Pharmaxis has also developed two respiratory products which are approved and supplied in global markets, generating ongoing revenue.

Pharmaxis is developing its drug PXS-5505 for the bone marrow cancer myelofibrosis which causes a build up of scar tissue that leads to loss of production of red and white blood cells and platelets. The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to PXS-5055 for the treatment of myelofibrosis and permission under an Investigational Drug Application (IND) to progress a phase 1c/2 clinical trial that began recruitment in Q1 2021. PXS-5505 is also being investigated as a potential treatment for other cancers such as pancreatic cancer. The FDA has granted an IND for a phase 1c/2a clinical trial in liver cancer.

Other drug candidates being developed from Pharmaxis' amine oxidase chemistry platform are targeting fibrotic diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis; and inflammatory diseases. PXS-6302 is being studied as a first in class topical drug that inhibits the enzymes involved in formation and maintenance of scars

Pharmaxis has developed two products from its proprietary spray drying technology that are manufactured and exported from its Sydney facility; Bronchitol® for cystic fibrosis, which is approved and marketed in the United States, Europe, Russia and Australia; and Aridol® for the assessment of asthma, which is approved and marketed in the United States, Europe, Australia and Asia.

Pharmaxis is listed on the Australian Securities Exchange (PXS). Its head office, manufacturing and research facilities are in Sydney, Australia. www.pharmaxis.com.au

Forward-looking statements

Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential of products and drug candidates. All forward-looking statements included in this media release are based upon information available to us as of the date hereof. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. These forward-looking statements are not guarantees or predictions of future results, levels of performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this

document. For example, despite our efforts there is no certainty that we will be successful in developing or partnering any of the products in our pipeline on commercially acceptable terms, in a timely fashion or at all. Except as required by law we undertake no obligation to update these forward-looking statements as a result of new information, future events or otherwise.

For personal use only